The drug Ozempic, developed by Novo Nordisk, is facing a class-action lawsuit in which approximately 1,800 people are seeking nearly $2 billion in damages, claiming that the treatment caused them serious health problems.
According to the plaintiffs, the drug is linked to cases of
severe vision loss, as well as the development of an aggressive type of thyroid
cancer. The plaintiffs argue that these ailments appeared after using the drug
and that they were not adequately warned about the potential risks associated
with its use.
The legal action seeks a court ruling on whether the
manufacturer is liable for the information provided regarding the drug's safety
and whether the alleged side effects are causally related to the treatment. The
plaintiffs are also seeking compensation for medical expenses, physical
injuries, and other damages resulting from the health problems they claim to
have suffered.
Ozempic, whose active ingredient is semaglutide, was
approved for the treatment of type 2 diabetes and subsequently gained
widespread popularity for its weight-loss effects, significantly increasing its
use in various countries. However, its growing demand has also led to increased
scrutiny from health authorities and the medical community regarding its
potential adverse effects.
To date, Novo Nordisk has maintained that the safety and
efficacy of Ozempic are supported by clinical studies and by the assessments
conducted by the regulatory agencies that authorized its marketing. The company
has also stated that it will continue to cooperate with the relevant
authorities and defend its position in legal proceedings.
It is important to note that filing a lawsuit does not
constitute proof of liability nor does it imply that the allegations have been
proven in court. It will be up to the courts to analyze the scientific and
legal evidence presented by both parties before issuing a ruling on the case.